Background {#Sec1}
==========

Coronary artery disease (CAD) is one of the most common causes of death worldwide, with over 7 million deaths each year \[[@CR1]\]. According to the WHO, in 2011, China has the second-largest number of CAD deaths in the world. CAD is a complex disease with both genetic and environmental components, with genetic factors accounting for 40--50% of the etiology of CAD \[[@CR2]\]. Treatment for CAD depends on drug therapy and percutaneous coronary intervention (PCI). As the recommended therapy when symptoms persist despite drug treatment, PCI is important not only in acute coronary syndrome (ACS) but also in stable CAD. Although application of PCI has greatly improved ACS patient prognosis, prolonged life and enhanced quality of life, some patients suffer from in-stent restenosis (ISR), which can lead to relapse and a poor prognosis \[[@CR3]\]. Thus, ISR has become a common problem for PCI.

Understanding the mechanisms involved in the development of ISR is crucial for its prevention. The direct cause of ISR is stent-induced endothelial injury. Delayed reendothelialization in the stented segment can result in activation of cytokines and growth factors, which in turn stimulate vascular smooth muscle cell (VSMC) differentiation, migration and proliferation \[[@CR4]\], followed by narrowing of the coronary lumen \[[@CR5]\]. Moreover, oxidative stress promotes the reactivity of aldehydes, such as acetaldehyde, malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), further aggravating endothelial dysfunction. Human mitochondrial aldehyde dehydrogenase 2 (encoded by the *ALDH2* gene) is a key enzyme that metabolizes and eliminates 4-HNE \[[@CR6]\]. Previous studies have indicated that mice with ALDH2 functional defects exhibit increased sensitivity to externally induced oxidative stress \[[@CR7]\] and that inhibition of ALDH2 by oxidative stress is significantly associated with cardiac dysfunction in diabetic rats \[[@CR8]\]. Therefore, ALDH2 is considered to be a marker and protector against oxidative stress \[[@CR9]\], and deletion of the gene can increase oxidative stress.

There is evidence that genetic factors such as single-nucleotide polymorphism in the genes encoding human vascular endothelial cell growth factor (*VEGF)* and endothelial nitric oxide synthase (*eNOS)* are related to a risk of ISR \[[@CR10]\], though it remains unknown whether polymorphisms in genes involved in ROS metabolism are also associated with this risk. The human *ALDH2* gene is located on chromosome 12 (12q24.2), and the loss-of-function polymorphism rs671 (Glu504Lys or *ALDH2\*2*) in *ALDH2* decreases ALDH2 activity by approximately 90% \[[@CR11]\]. Due to the important role of *ALDH2* in 4-HNE metabolism and in the 4-HNE-mediated oxidative stress in endothelial dysfunction, we speculate the *ALDH2\*2* polymorphism might affect the risk of ISR after PCI by influencing vascular endothelial function.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This study was conducted at Xiangya Hospital of Central South University and First Affiliated Hospital of Zhengzhou University. All patients were diagnosed with ACS and underwent PCI within 4 weeks after their diagnosis. All patients returned to the hospital for reexamination by coronary angiography about one year after discharge according to individual clinical practices. The inclusion criterion was a diagnosis of in-stent restenosis via coronary angiography after PCI treatment during the one-year follow-up period. The exclusion criteria were as follows: (1) presence of severe heart valve disease; (2) history of thrombosis; (3) cerebrovascular accident in the 4 months before the procedure; (4) bleeding susceptibility; (5) malignant disease such as tumor; (6) platelet dysfunction; (7) acute or chronic inflammatory disease; (8) incomplete information. A 5-ml sample of peripheral blood was drawn from all patients into ethylenediaminetetraacetic acid (EDTA) tubes and at centrifuged at 3000 rpm for 10 min; the plasma and blood cells were separated and stored at − 20 °C. Genomic DNA was extracted from the blood cells. A questionnaire and case registration form were used to record in detail the reasons for readmission, basic information, clinical presentation, coronary angiograph results, the event of IRS, and the degree of restenosis. The time of all patients to reexamination the angiography was recorded and the time from PCI to reexamination were calculated. Smoker vs non-smoker was distinguished by no cigarette smoking for half a year; drinker vs non-drinker was distinguished by no alcohol drinking for half a year. Hypertension, hyperlipidemia and diabetes mellitus were defined according to European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension \[[@CR12]\], the third Report of The National Cholesterol Education Program (NCEP) \[[@CR13]\] and American Diabetes Association criteria \[[@CR14]\], respectively.

Definition of in-stent restenosis {#Sec4}
---------------------------------

The definition of ISR was greater than 50% reduction in the luminal diameter within the stent, distal segments adjacent to the stent or the 5-mm proximal, as based on follow-up angiography \[[@CR12]\]. In patients with multiple restenosis, the number of lesions were recorded. The results of the luminal narrowing and in-stent restenosis were confirmed by two experienced interventional cardiologists according to ESC guidelines for cardiovascular diagnoses.

*ALDH2\*2* (Glu504Lys) polymorphism assay {#Sec5}
-----------------------------------------

DNA was extracted by phenol-chloroform extraction performed according to previously described protocols \[[@CR15]\]. The polymerase chain restriction fragment length polymorphism (PCR-RFLP) method was employed for genotyping using the following primers: upstream, 5′- GATGTGGAGGTTGCAACGAG − 3′; downstream, 5′- CCTACAGGCCTTGGCGTATA − 3′. The PCR amplification system used 15 ng of genomic template and 10 μM primers with the following reaction conditions: 36 cycles of 94 °C for 45 s, 60 °C for 45 s, and 72 °C for 1 min, followed by extension at 72 °C for 10 min and storage at 4 °C. The PCR product (3 μL) was digested using the restriction endonuclease Eco57 I at 37 °C overnight and electrophoresed through a 1.5% agarose gel with ethidium bromide staining. The PCR products were sent to Sangon Biotech Company for sequencing. Data were analyzed with the use of Chromas version 2.33. Genomic sequences of *ALDH2* obtained from GenBank (NC_000012.12:111766887--111809985) were used as references.

Statistical analysis {#Sec6}
--------------------

The t test and chi-square test were performed with SPSS 20.0 software, and logistic regression analysis was performed using R statistical software version 3.3.3. Measurement data are expressed as the mean ± standard deviation and median (interquartile range). Analysis of continuous variables such as biochemical tests was performed using the t test and non-normally distributed data was performed using Mann-Whitney test or Kruskal-Wallis H test. Analysis of categorical variables such as sex, risk factors, coronary artery lesions, medications and *ALDH2* genotype were analyzed by the chi-square test. Logistic regression analysis was applied to assess the relationship between genotype and ISR risk. The independent variables examined were based on previous studies \[[@CR16], [@CR17]\]. A *p* value less than 0.05 was considered to indicate statistical significance.

Results {#Sec7}
=======

Eligible patients and clinical characteristics between ISR and non-ISR patients {#Sec8}
-------------------------------------------------------------------------------

According to our inclusion and exclusion criteria, 531 subjects were enrolled in this study from 2015 to 2018 (Fig. [1](#Fig1){ref-type="fig"}). All of the patients visited the hospital and were subjected to repeated coronary angiographies after PCI. ISR was observed in 183 (34.5%) patients. The clinical characteristics of the patients enrolled in this study are listed in Table [1](#Tab1){ref-type="table"}. Baseline demographics were balanced between the ISR group and the non-ISR group. Compared with non-ISR patients, ISR patients had higher HBA1C levels but lower thrombocytocrit levels. The incidence of type 2 diabetes and the use of clopidogrel and statins were notably overrepresented in patients with ISR. However, no differences in age, sex, follow-up period, risk factors, biochemical tests, or other medical treatments were found between the patients with and without ISR. Despite similarities with regard to the site of coronary lesion and degree of stenosis before PCI, patients with complicated coronary artery disease and multivessel disease were found to be more likely to develop ISR (Table [1](#Tab1){ref-type="table"}).Fig. 1Patients selection flowchartTable 1Baseline characteristics of patients who undergoing PCIVariableTotal (*n* = 531)ISR (*n* = 183)no-ISR (*n* = 348)*p*-valueAge, years59.4 ± 9.858.8 ± 9.860.5 ± 9.80.069Male, n (%)350 (65.9)114 (62.3)236 (67.4)0.202Follow-up period, days363 (289--386)364 (294--391)363 (285--385)0.471Risk factors, n (%) Cigarette smoking143 (26.9)42 (23)101 (29)0.134 Alcohol drinking96 (18.1)29 (15.8)67 (19.3)0.332 Hypertension247 (46.5)92 (50.3)155 (44.5)0.208 Diabetes mellitus115 (21.7)49 (26.8)66 (19.0)0.038 Hyperlipemia31 (5.8)6 (3.3)25 (7.2)0.068Biochemical tests Thrombocytocrit, mmol/L0.19 ± 0.070.18 ± 0.040.19 ± 0.080.041 MPV, fl9.03 ± 3.08.85 ± 1.79.12 ± 3.50.338 HBA1C, %6.23 ± 1.96.53 ± 1.96.07 ± 1.90.007 Glucose, mmol/L5.43 ± 1.95.6 ± 1.95.35 ± 1.90.16 Serum creatinine, μmol/L75.7 ± 35.271.8 ± 22.477.8 ± 40.20.06 TC, mmol/L3.82 ± 1.13.79 ± 1.13.83 ± 1.20.673 TG, mmol/L1.62 ± 1.11.59 ± 0.81.64 ± 1.20.646 HDL, mmol/L1.07 ± 0.31.07 ± 0.31.07 ± 0.30.997 LDL, mmol/L2.3 ± 0.92.3 ± 0.92.29 ± 0.90.895Coronary artery lesions, n (%)\< 0.001 Single-vessel disease225 (42.4)64 (35)161 (46.3) Double-vessel disease168 (31.6)49 (26.8)119 (34.2) Triple-vessel disease138 (26)70 (38.3)68 (49.3)Medications, n (%) Clopidogrel420 (79.1)156 (85.2)264 (75.9)0.011 Ticagrelor119 (22.4)37 (20.2)82 (23.6)0.38 Statins505 (95.1)179 (97.8)326 (93.7)0.036 ACEI/ARB196 (37)75 (41)121 (34.9)0.166 β-blocker383 (72.1)133 (72.7)250 (71.8)0.838 CCB158 (29.9)58 (32)100 (28.8)0.442 Antidiabetic therapy264 (49.7)99 (54.1)165 (47.4)0.143 Nitrate520 (97.9)181 (98.9)339 (97.4)0.251*ALDH2* genotype, n (%)0.028 *ALDH2 \*1/\*1*365 (68.7)115 (62.8)250 (71.8) *ALDH2 \*1/\*2*151 (28.4)59 (32.2)92 (26.4) *ALDH2 \*2/\*2*15 (2.8)9 (4.9)6 (1.7)Note: This statistical analysis was performed by SPSS 20.0 software. *MPV* Mean Platelet Volume, *HBA1C* Hemoglobin A1c, *TC* Total Cholesterol, *TG* Triglyceride, *HDL* High Density Lipoprotein, *LDL* Low Density Lipoprotein, *ACEI* Angiotensin-Converting Enzyme Inhibitors, *ARB* Angiotensin Receptor Blocker, *CCB* Calcium channel blocker

Genotype distribution of the *ALDH2\*2* polymorphism in ISR and non-ISR patients {#Sec9}
--------------------------------------------------------------------------------

The genotype distribution of the *ALDH2\*2* polymorphism is shown in Fig. [2](#Fig2){ref-type="fig"}. Among the 531 patients, 365 (68.7%) were the wild-type allele (*ALDH2\*1/\*1*), 151 (28.4%) carried the heterozygous (*ALDH2\*1/\*2*) allele and 15(2.8%)carried the mutant homozygote allele (*ALDH2\*2/\*2*). As the *ALDH2\*2* polymorphism is reportedly dominant, carriers of *ALDH2\*2* were combined for the ensuing association analysis \[[@CR2]\]. As shown in Table [1](#Tab1){ref-type="table"}, carriers of the *ALDH2\*2* allele were notably overrepresented among the ISR patients(*p* = 0.028).Fig. 2Genotyping Results of the *ALDH2*. Panel **a** was the results of the measure sequence: wild genotype of *ALDH2 \*1/\*1*, heterozygote genotype of *ALDH2 \*1/\*2*, homozygous mutant genotype of *ALDH2 \*2/\*2*. Panel **b** was the results of the *ALDH2* by PCR-RFLP: Sample 1 represents the heterozygote genotype of *ALDH2 \*1/\*2*, sample 2 and sample 3 represents the wild genotype of *ALDH2 \*1/\*1*, sample 4 represents the homozygous mutant genotype of *ALDH2 \*2/\*2*, sample M represents marker

Association of the *ALDH2\*2* polymorphism with ISR risk {#Sec10}
--------------------------------------------------------

The results of the chi-square test revealed obvious difference in the prevalence of diabetes mellitus (*p* = 0.038), coronary artery lesions (*p* \< 0.01) and the use of clopidogrel (*p* = 0.011) and statins (*p* = 0.036) between the ISR and non-ISR patients. Due to the low frequency of the mutant allele, heterozygotes with minor allele homozygotes were combined for comparison with wild-type allele homozygotes. Ten variables, including age, alcohol drinking, cigarette smoking, diabetes mellitus, coronary artery lesions, *ALDH2* genotype and medications (clopidogrel, statins, ACEI/ARB, and nitrite) were selected for univariate regression, and the results showed that patients with type 2 diabetes (OR = 1.647, 95% CI: 1.029--2.611, *p* = 0.035), carriers of the *ALDH2\*2* allele (OR = 1.537, 95% CI: 1.005--2.339, *p* = 0.046) and those who use of the antiplatelet medication clopidogrel (OR = 1.697, 95% CI: 1.018--2.934, *p* = 0.049) were at an increased risk for ISR (Table [2](#Tab2){ref-type="table"}). In multivariate analysis, a significant association between coronary artery lesions (OR = 1.508, 95% CI: 1.193--1.911, *p* = 0.006, Table [2](#Tab2){ref-type="table"}) and ISR was observed, and the use of clopidogrel for antiplatelet therapy was also a risk factor for ISR (OR = 1.680, 95% CI: 1.035--2.794, *p* = 0.039); in contrast, the association of *ALDH2* genotype with the risk of IRS was only marginal (OR = 1.50, 95% CI: 0.96--2.32, *p* = 0.073). Among the 183 patients diagnosed with ISR, the median (interquartile range) of *ALDH2 \*1/\*1* was 70 (50--90) %, *ALDH2 \*1/\*2* was 85 (70--90) % and *ALDH2 \*2/\*2* was 80 (60--92.5) %. Analysis of correlation was performed using the Kruskal-Wallis H test and the result suggested that there was a statistically significant difference in the percentage diameter stenosis between the three groups (*p* = 0.034, Fig. [3](#Fig3){ref-type="fig"}).Table 2Risk Factors of in-sent retenosis by univariate and multivariate regression in all patientsVariableUnivariate analysisMultivariate analysisOR (95%)*p*-valueOR (95%)*p*-valueAge1.01 (0.989--1.030)0.3781.009 (0.990--1.030)0.32Alcohol drinking (vs non)0.877 (0.512--1.460)0.6221.230 (0.651--2.319)0.521Cigarette smoking (vs non)0.807 (0.506--1.264)0.3570.654 (0.377--1.113)0.123Diabetes mellitus (vs non)1.647 (1.029--2.611)0.0351.424 (0.909--2.221)0.12Coronary artery lesions (vs single-vessel disease)1.278 (0.994--1.642)0.0571.508 (1.193--1.911)0.006*ALDH2 \*2* carriers vs *ALDH2 \*1* homozygotes1.537 (1.005--2.339)0.0461.448 (0.965--2.168)0.073Clopidogrel1.697 (1.018--2.934)0.0491.680 (1.035--2.794)0.039Statins2.924 (0.992--12.503)0.0852.493 (0.867--9.054)0.118ACEI/ARB1.317 (0.872--1.982)0.1881.052 (0.709--1.556)0.799Nitrite1.739 (0.441--11.505)0.4831.367 (0.277--9.903)0.718Note: This statistical analysis was performed by R statistical software version 3.3.3. *ACEI* Angiotensin-Converting Enzyme Inhibitors, *ARB* Angiotensin Receptor BlockerFig. 3Correlation of genotype distribution and changes in percentage diameter stenosis. Correlation of genotype distribution and changes in percentage diameter stenosis was analyzed in 183 patients diagnosed with ISR. Among them, the median (interquartile range) of *ALDH2 \*1/\*1* was 70 (50--90) %, *ALDH2 \*1/\*2* was 85 (70--90) % and *ALDH2 \*2/\*2* was 80 (60--92.5) %. Kruskal-Wallis H test was used to analyze the correlation, the result suggested that there was a statistically significant difference in the percentage diameter stenosis between the three groups (*p* = 0.034)

Association of the *ALDH2\*2* polymorphism with ISR risk stratified by diabetes {#Sec11}
-------------------------------------------------------------------------------

Among ISR patients with diabetes, 27 (55.1%) carried the *ALDH2\*1/\*1*, 20 (40.8%) carried the *ALDH2\*1/\*2* allele, and 2 (4.1%) carried the *ALDH2\*2/\*2* allele (Table [3](#Tab3){ref-type="table"}). Of the non-ISR patients with diabetes, 54 (81.8%) carried the *ALDH2\*1/\*1* allele, 11 (16.7%) carried the *ALDH2\*1/\*2* allele, and 1 (1.5%) carried the *ALDH2\*2/\*2* allele (Table [3](#Tab3){ref-type="table"}). The results of the chi-square test showed significant overrepresentation of *ALDH2\*2* carriers among ISR patients with diabetes (*p* = 0.008). Of the ISR patients who did not have diabetes, equal proportions of *ALDH2\*1/\*1*, *ALDH2\*1/\*2* and *ALDH2\*2/\*2* were 88 (65.7%), 39 (29.1%), and 7 (5.2%), respectively. No difference in *ALDH2* genotype distribution between the ISR and non-ISR patients was observed among those without diabetes (*p* = 0.139, Table [3](#Tab3){ref-type="table"}).Table 3The genotype of *ALDH2* distribution in patients with or without diabetes mellitusGenotype, n (%)TotalISRnon-ISR*p*-valuePatients with diabetes0.008 *ALDH2 \*1/\*1*81 (70.4)27 (55.1)54 (81.8) *ALDH2 \*1/\*2*31 (27)20 (40.8)11 (16.7) *ALDH2 \*2/\*2*3 (2.6)2 (4.1)1 (1.5)Patients without diabetes0.139 *ALDH2 \*1/\*1*284 (68.3)88 (65.7)196 (69.5) *ALDH2 \*1/\*2*120 (28.8)39 (29.1)81 (28.7) *ALDH2 \*2/\*2*12 (2.9)7 (5.2)5 (1.8)Note: This statistical analysis was performed by SPSS 20.0 software

To investigate whether the occurrence of diabetes affects the relationship between the *ALDH2\*2* polymorphism and ISR risk, an additional association analysis was performed by stratification of patients with or without diabetes mellitus. In Table [4](#Tab4){ref-type="table"}, 8 variables including age, alcohol consumption, cigarette smoking, coronary artery lesions, *ALDH2* genotype, and clopidogrel, statin and ACEI/ARB use are shown with their *p* values from univariate regression; among these, only *ALDH2\*2* (OR = 3.667, 95% CI: 1.606--8.727, *p* = 0.002) genotype was associated with a significantly increased risk for IRS among patients with diabetes. After entering these 8 variables into the multivariate model, the results were the same as those of univariate regression, with only *ALDH2\*2* (OR = 4.053, 95% CI: 1.668--10.449, *p* = 0.003) carriers showing significantly increased risk. Similarly, univariate regression and multivariate regression were employed to assess risk factors in non-diabetic patients, with no association found between *ALDH2* genotype and ISR (Table [4](#Tab4){ref-type="table"}). Interestingly, both univariate and multivariate regression analyses indicated that coronary artery lesions were not associated with the risk of ISR among diabetic patients (OR = 1.095, 95% CI: 0.68--1.767, *p* = 0.709; OR = 1.068, 95% CI: 0.626--1.818, *p* = 0.808); however, in non-diabetic patients, the number of coronary artery lesions was significantly associated with ISR in both univariate and multivariate regression analyses (OR = 1.746, 95% CI: 1.355--2.261, *p* \< 0.01; OR = 1.677, 95% CI: 1.284--2.2, *p* \< 0.01). Additionally, the use of clopidogrel was associated with ISR in patients without diabetes (OR = 1.918, 95% CI: 1.129--3.382, *p* = 0.019; OR = 1.857, 95% CI: 1.073--3.329, *p* = 0.031) but not in those with diabetes (OR = 1.472, 95% CI: 0.551--4.221, *p* = 0.451; OR = 0.899, 95% CI: 0.297--2.829, *p* = 0.851).Table 4Risk Factors of in-sent retenosis by univariate and multivariate regression in patients with or without diabetes mellitusVariableunivariate analysismultivariate analysisOR (95%)*p*-valueOR (95%)*p*-valueDiabetesAge1.018 (0.974--1.065)0.4311.014 (0.966--0.966)0.574Alcohol drinking (vs non)0.644 (0.164--2.183)0.4950.944 (0.178--4.66)0.944Cigarette smoking (vs non)0.636 (0.187--1.929)0.4390.436 (0.093--1.113)0.267Coronary artery lesions (vs single-vessel disease)1.095 (0.680--1.767)0.7091.068 (0.626--1.818)0.808*ALDH2 \*2* carriers vs *ALDH2 \*1* homozygotes3.667 (1.606--8.727)0.0024.053 (1.668--10.449)0.003Clopidogrel1.472 (0.551--4.221)0.4510.899 (0.297--2.829)0.851Statins1.500 (0.140--32.83)0.7431.817 (0.145--2.794)0.651ACEI/ARB1.376 (0.654--2.914)0.4001.205 (0.528--2.748)0.656Non-diabetesAge1.015 (0.995--1.037)0.1451.009 (0.987--1.031)0.424Alcohol drinking (vs non)0.868 (0.508--1.445)0.5911.177 (0.581--2.374)0.649Cigarette smoking (vs non)0.801 (0.505--1.253)0.3370.694 (0.379--1.241)0.225Coronary artery lesions (vs single-vessel disease)1.746 (1.355--2.261)\< 0.0011.677 (1.284--2.200)\< 0.001*ALDH2 \*2* carriers vs *ALDH2 \*1* homozygotes1.191 (0.766--1.841)0.4331.112 (0.693--1.774)0.657Clopidogrel1.918 (1.129--3.382)0.0191.857 (1.073--3.329)0.031Statins3.333 (1.117--14.329)0.0552.594 (0.839--11.376)0.138ACEI/ARB1.210 (0.785--1.855)0.3851.008 (0.635--1.586)0.974Note: This statistical analysis was performed by R statistical software version 3.3.3. *ACEI* Angiotensin-Converting Enzyme Inhibitors, *ARB* Angiotensin Receptor Blocker

Discussion {#Sec12}
==========

This study analyzed the association between the *ALDH2\*2* polymorphism and risk for ISR one year after PCI. Previous studies have demonstrated that the rate of the *ALDH2\*2* polymorphism is approximately 30--50% in Asians, but the frequency worldwide is only approximately 8% \[[@CR18]\]. Therefore, analysis of the clinical relevance of this polymorphism is important for Asian populations. Several previous studies have reported that the *ALDH2\*2* polymorphism is a risk factor for the course of CAD, especially in Asians \[[@CR18]\]. For example, Yavari et al. found the *ALDH2\*2* polymorphism to be an independent genetic risk factor for CAD in the Han Chinese population \[[@CR19]\]. In addition, *ALDH2*-deficient mice exhibit significantly increased production of mitochondrial ROS and endothelial dysfunction after prolonged treatment with acetaldehyde \[[@CR20]\]. Indeed, oxidative stress due to the production of reactive oxygen species (ROS) and inflammation are key pathophysiological processes for the development of ISR and for in-stent atherosclerosis \[[@CR21]\]. ROS can cause endothelial dysfunction and directly promote VSMC proliferation and migration by inducing inflammation. ROS can also promote the formation of lipid free radicals and lipid peroxides, which result in the formation of reactive aldehydes, such as acetaldehyde, MDA and 4-HNE, further aggravating endothelial dysfunction. PC12 cells deficient in *ALDH2* are highly sensitive to 4-HNE-induced oxidative damage and accumulate proteins that are modified by 4-HNE. Ethanol can reduce 4-HNE levels by activating *ALDH2* and thus shows cardioprotective effects during ischemia-reperfusion injury \[[@CR22], [@CR23]\]. Therefore, ALDH2 is considered to be a marker of and protector against oxidative stress, and defects in *ALDH2* can increase oxidative stress \[[@CR24]\]. Asymmetric dimethylarginine (ADMA) is a newly discovered risk factor for cardiovascular disease that acts via inhibition of NO synthase and decreased NO production, which leads to vascular endothelial dysfunction. Evidence has shown that 4-HNE can inhibit expression of miR-21, a microRNA that suppresses expression of the ADMA-inactivating enzyme dimethylarginine dimethylaminohydrolase 1 (DDAH1). In addition 4-HNE can directly form an adduct with DDAH1, inhibiting DDAH1 activity and promoting endothelial dysfunction \[[@CR25]\]. The *ALDH2\*2* polymorphism is associated with CAD susceptibility \[[@CR15]\], and the mechanism of this effect is partially explained by decreased DDAH1 expression and increased ADMA levels in endothelial cells. The stent-induced endothelial injury and delayed reendothelialization by DES is critical for the development of ISR, and interindividual differences in reendothelialization capacity might influence the risk of ISR and the prognosis of CAD after PCI \[[@CR26], [@CR27]\].

In this study, we analyzed 531 CAD patients who had received PCI and were diagnosed with in-stent restenosis about one year after the procedure. Patients were grouped according to the occurrence of ISR. Frequency matching was also performed for all variables potentially associated with a risk of ISR to evaluate the pure impact of the *ALDH2* polymorphism. The overall frequency of heterozygosity for the polymorphism was 31.2% in this study, and this frequency was comparable with that of other studies \[[@CR18]\]. Our results showed that there was a statistical difference in the changes in percentage diameter stenosis among the three genotypes of 183 patients diagnosed with ISR. But it was different from our expectation that the percentage diameter stenosis of *ALDH2 \*1/\*2* was the highest, which may be caused by low frequency of *ALDH2 \*2/\*2*. We acknowledged this study's limitation that there is no specific value degree of stenosis for those patients who had reduction in in-stent luminal diameter of less than 50%, and we could not acquire their angiographic images for technical reason. Furthermore, our results indicated that *ALDH2\*2* carriers were at an increased risk of ISR, especially among those with diabetes. Wang et al. observed that myocardial MDA contents and ROS levels were significantly increased in diabetic rats, which also showed reduced left ventricular ejection fraction and fractional shortening accompanied by decreased *ALDH2* expression and activity. We hypothesized that a diabetic status may result in increased oxidative stress, which may include an increase in endogenous aldehydes levels. Furthermore, the level of oxidative stress in *ALDH2\*2* patients may be increased, thus accounting for the delayed reendothelialization of target vessels after DES-induced endothelial injury and the increased risk for ISR after PCI. In addition, the risk of ISR is higher in the Asian population than in European and American populations, perhaps because *ALDH2\*2* is more commonly found in Asians than in other populations \[[@CR28]\].

Study limitation {#Sec13}
----------------

There are several limitations of this study. First, the sample size was small. Moreover, for analyzing the changes in percentage diameter stenosis as a continuous variable, we had to exclude those patients with a reduction of less than 50% in in-stent luminal diameter, because the angiographic images were not re-accessible for a technical reason. A prospective study with a larger sample size is required to validate our findings. Second, given that the distribution of different gene mutations can vary depending on ethnicity, our results might not be repeatable in other ethnic populations. Third, data regarding BMI, stent type, and angiographic and echocardiographic information were not collected at baseline, though these data might have prognostic significance. Lastly, the major weakness of this study is the lack of systematic follow-up of all patients, which may have resulted in selection bias. Although we showed no association between *ALDH2* genotype and ISR, we cannot ensure that our eligible cohort is representative of the population due to the loss patients because of poor compliance and incomplete follow-up.

Conclusion {#Sec14}
==========

Our findings indicate that *ALDH2\*2* (heterozygous genotype) was not associated with ISR one year after PCI. Although our study demonstrated that *ALDH2\*2/1/ALDH2\*2/2* were not associated with ISR after PCI, the well-documented cardiovascular protection provided by the *ALDH2\*1/1* genotype is unquestionable. Furthermore, the prevalence of nonfunctional alleles in different ethnic populations should be considered to achieve a consensus regarding the characteristics of these genotypes \[[@CR2]\].
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===============
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Additional file 1:**Table S1**. Clinical information of all patients in this study. (XLSX 90 kb)

4-HNE

:   4-Hydroxynonenal

ACEI

:   Angiotensin-converting enzyme inhibitor
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:   Acute coronary syndrome

ADMA

:   Asymmetric Dimethylarginine

ALDH2

:   Aldehyde dehydrogenase 2

ARB

:   Angiotensin receptor blocker

BMS

:   Bare metal stent
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:   Coronary artery disease
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:   Calcium channel blocker

DDAH1

:   Dimethylarginine Dimethylaminohydrolase 1
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:   Drug-eluting stent
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:   Ethylenediaminetetraacetic acid

eNOS

:   Endothelial nitric oxide synthase

HBA1C

:   Hemoglobin A1c

HDL

:   High-density lipoprotein

ISR

:   In-stent restenosis

LDL

:   Low-density lipoprotein

MDA

:   Malondialdehyde

MPV

:   Mean platelet volume

PCI

:   Percutaneous coronary intervention

ROS

:   Reactive oxygen species

SNP

:   Single-nucleotide polymorphism

TC

:   Total cholesterol

TG

:   Triglyceride

VEGF

:   Vascular endothelial cell growth factor

VSMC

:   Vascular smooth muscle cell

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Lizhi Lv and Weijie Ye contributed equally to this work.

Not applicable.

LZL designed the study and analyzed the data; WJY wrote the paper; PYS, YBC, JY and CMZ collected the clinical data; XPC contribute the study design and FYL approved the final manuscript. All authors have read and approved the MS.

The study was supported by the fundamental research funds for the Central Universities of Central South University (Program: 2018zzts081), National Natural Science Foundation of China (81873494 to Fanyan Luo), and Hunan Natural Science Foundation (2018JJ2665 to Fanyan Luo), all funding bodies have played a role in designing research and collection, analyzing and interpreting data, and writing the manuscript.

All data generated or analyzed during this study are included in this published article Additional file [1](#MOESM1){ref-type="media"}.

This study was approved by the Ethics Committee of the Xiangya Hospital, Central South University, Changsha (201803732). We obtained individual verbally permission of participants before the study.

Not applicable.

None of the authors declares competing interests regarding this study.
